We have our new newsletter is available!! New news and articles letting you know the latest news in regards to CLL and the Blood Cancer Research Fund. Special thanks to Carolina Bump for her tireless efforts to get this information together!
For the last couple years, the UC San Diego Moores Cancer Center CLL program under the leadership of Dr. Thomas Kipps has been at the forefront of leading clinical trials for the use of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with CLL. We are happy to announce that both iburtinub and obinutuzumab have been approved for treatment. Both drugs are considered “breakthrough therapies” under a program established by Congress last year. The new Breakthrough Therapy Designation indicates that the medicines may offer substantial improvement over standard treatments for patients with serious or life-threatening diseases. Both drugs demonstrate a shift for treatments away from chemotherapy.
Gazyva is an antibody that binds to CD20 a protein found on the surface of B cells and causes the cells, which are cancerous to die. It is the the first breakthrough monoclonal antibody drug to win FDA approval and will be used to treat patients with CLL who have not been previously treated. It will be used in combination with chlorambucil to attack cancerous cells. Patients who participated in the trial demonstrated a significant improvement in progression-free survival with an average of 23 months. Gazyva is being approved with a boxed warning regarding Hepatitis B virus reactivation and a rare disorder that damages the material that covers and protects nerves in the white matter of the brain (progressive multifocal leukoencephalopathy). These are known risks with other monoclonal antibodies in this class and rare cases were identified in participants on other trials of Gazyva. Patients should be advised of these risks and assessed for Hepatitis B virus and reactivation risk.
Imbruvica was approved for breakthrough treatment for relapses of mantle cell lymphoma and has also recently been applied for approval to treat CLL. It is an oral treatment and its approval was based the response rates of 111 patients. 65 percent of patients who received Imbruvica had a complete or partial response. Pharmacyclics officials said the label contained no black box warnings and no contraindications. Safety data during the drug’s pivotal trial showed the most common Grade 3 or 4 nonhematological adverse reactions (≥ 5 percent) included pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue and skin infection
The FDA approved the use of ibrutinib, now known as Imbruvica, for the treatment of patients with mantle cell lymphoma. Ibrutinib is the second drug with ‘breakthrough therapy designation’ to receive FDA approval. This effort is appaluded and supported by the Leukemia and Lymphoma Society (LLS). We are also proud to mention that the program is lead by former BCRF fellow, Danelle James, MD, MS. (Medical Director for Pharmacyclics)
To improve outcomes of patients with Richter syndrome (RS) and relapsed/refractory chronic lymphocytic leukemia (CLL), we modified the OFAR1 regimen (oxaliplatin and cytarabine doses of the oxaliplatin, fludarabine, cytarabine, and rituximab) for this phase I-II study (OFAR2).
Have you seen the new Jacob’s Medical Center building being built just across from the Moores Cancer Center? To read more about the project and the incredible commitment to creating a healthier world, CLICK HERE!
The $839 million facility is part of a multi-billion dollar university investment in the future of health care for the entire region. It will allow UC San Diego Health System to fulfill its potential of becoming one of the country’s premier academic health systems.
The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia (CLL), the most common adult leukemia in the United States. Read More…
Andrew Schorr from Patient Power in partnership with the CLL Global Research Foundation interview Dr. Thomas Kipps, Director of the Blood Cancer Research Fund and the CLL Research Consortium about the use of rituximab, a monoclonal antibody used to treat patients with chronic lymphocytic leukemia
Dr. Thomas Kipps and scientists from his research laboratory at the UC San Diego Moores Cancer Center discover an association between a protein called ROR1 and EMT, a process that occurs during embryogenesis.
Stopping cancer’s spread: New protein found to control deadly cancer metastasis
Researchers have found a critical element that may explain why some cancers spread farther and faster than others, a discovery that could lead to one of the Holy Grails of cancer treatment: containing the disease.
Scientists from the University of California, San Diego School of Medicine, Dr. Thomas J. Kipps and colleagues, have identified a protein that seems to serve as a switch, regulating the spread of cancer from the primary tumor to distant spots in the body – a process known as metastasis. The protein is used by embryo cells during early development, but then disappears from the body after an individual comes out of the womb.